[1] |
陈明弟,张瑞辉,成明建,等.全自动发药机内不同剂型拆零药品存放期限及管理模式探析[J].北方药学,2020,17(3):170-171.
|
[2] |
国家药品监督管理局.药品经营质量管理规范[EB/OL].(2016-07-20)[2021-11.29].https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/bmgzh/20160720102601205.html.
|
[3] |
曹凯,钱佩佩,胡俊涛,等.美国重新包装药品有效期执法政策及对我国的启示[J].中国药房,2018,29(1):8-11.
|
[4] |
张明媛,陈丽湘,苏显财,等.医院药房常见拆零药品的稳定性研究与效期建议[J].海峡药学,2019,31(12):261-262.
|
[5] |
陈娇婷,陈思艺.医院拆零药品的分析与对策[J].山东化工,2015,44(17):98-99,103.
|
[6] |
林超.门诊药房拆零药管理存在的问题及对策[J].海峡药学,2020,32(1):201,221-222.
|
[7] |
朱丹清,严丽娜.医院药房调剂拆零药品时药品质量的影响原因与对策[J].中医药管理杂志,2021,29(2):179-180.
|
[8] |
张彦昭,文占权,刘传绪,等.医疗机构拆零药品质量管理的问题和建议[J].中国医药导刊,2017,19(11):1237-1241.
|
[9] |
吕锡亮,张跃文.某院药品拆零存在的问题与解决方案[J].中国医药指南,2013,11(21):775-776.
|
[10] |
孙玫.基层医院药房药品拆零调配中存在的问题及对策探讨[J].中国卫生产业,2017,14(27):170-171.
|
[11] |
杨晓.分析医院药房口服药品拆零调配中存在的问题及其应对措施[J].世界最新医学信息文摘,2019,19(14):202,205.
|
[12] |
潘江锋.合理完善拆零药品有效期管理的探讨[J].中医药管理杂志,2019,27(6):37-38.
|
[13] |
袁逾喆.药房拆零药品储存、调剂存在的问题及对策[J].中国医药指南,2012,10(8):620.
|
[14] |
刘鹏.总结住院药房拆零药品中的问题及改善措施[J].临床医药文献电子杂志,2019,6(85):183.
|
[15] |
周泉,李全良,方卫利.住院患者口服药物拆零调剂的思考与分析[J].中国药业,2014,23(24):95-96.
|
[16] |
杨东升,南楠,马玲云,等.美国重包装、重贴标和自有品牌经销药品的应用简介[J].中国新药杂志,2019,28(15):1815-1818.
|
[18] |
Murdaugh Lb.Competence Assessment Tools for Health System Pharmacies[J].Ann Pharmacother,2003,37(11):681-682.
|
[19] |
Bachenheimer BS.Manual for Pharmacy Technicians[M].America:Oxford University Press,2010:401-429.
|
[17] |
Mc Elhiney Lf.Unit-dose packaging and repackaging of solid and liquid dosage forms in an institutional setting[J].Int J Pharm Compd,2010,14(1):32-38.
|
[20] |
Okeke Cc,Bailey L,Medwick T,et al.Revised Usp Standards for Product Dating,Packaging,and Temperature Monitoring[J].Am J Health Syst Pharm,2000,57(15):1441-1445.
|
[21] |
Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products Guidance for Industry[S].2017.https://www.fda.gov/Drugs/Guidance Compliance Regulatory Information/Guidances/default.htm.
|
[22] |
Thompson Ca.FDA Outlines Conditions for Pharmacies to Repackage Drug Products[J].Am J Health Syst Pharm,2017,74(7):453-455.
|
[23] |
United States Pharmacopeial Convention Inc.USP39-NF34[S].Rockille:The United States Pharmacopeial Convention press,2015:270-272,808-809.
|
[24] |
Nguyen Rt,Sayeed Va.Repackaged Oral Dosage Forms:Beyond-use Dating and Product Safety Concerns[J].Am J Health Syst Pharm,2013,70(19):1724-1727.
|
[25] |
董光辉,赵柳入,叶明良,等.药品持续稳定性考察试验中温度超标的评估分析[J].临床合理用药杂志,2014,7(11):88-89.
|
[26] |
国家药品监督管理局.药品生产质量管理规范[EB/OL].(2011-01-17)[2021-12.6].https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20110117120001434.html.
|